Biologics

© Crescendo T cell therapy developer Crescendo Biologics Ltd (Crescendo) has named Eva-Lotta Allan Non-Executive Director of the company. The former CFO of Immunocore brings in …

Janssen Research & Development, LLC has accelerated the US market approval process of guselkumab, a human anti-IL-23 antibody licenced from MorphoSys AG, in moderate to severe …

Biomanufacturing: Why single-use? Source link

Nasdaq Stockholm has approved the company’s application subject to customary conditions. Bonesupport said it wants to broaden ist shareholder base through issuance of up to 18,518,519 …

Our data demonstrate that BI695501 and its reference product Humira (adalimumab) are comparable in terms of safety, efficacy and immunogenicity, Karsten Kissel, Head of Global Medical Affairs …

The authorisation triggered an milestone payment from Janssen Biotech, Inc. to MorphoSys AG (Martinsried, Germany), which had discovered and licenced the first ever approved IL23-blocking antibody …

Hans Loibner, Chief Executive Officer of the 11-year-old Viennese biotech, said: “Our recent achievement of obtaining the EU marketing authorisation for our most advanced project in …

Together with Amgen’s biosimilar version (Amjevita, adalimumab-atto) of Abbvie’s autoimmune blockbuster Humira, which received FDA approval last year, Boehringer Ingelheim (BI)’s Cyltezo (adalimumab-adbm) targets a market, …

Cost pressure, increased productivity of fed-batch processes, and the growing number of biologics tailored to increasingly small subpopulations are encouraging the adoption of smaller scale bioprocesses …

Under the agreement, the Bill & Melinda Gates Foundation will invest up to $40m in Immunocore to support development of Immunocore’s small protein molecules ImmTAV (a …